Antiretroviral drug resistance testing in patients with HIV-1 infection: A meta-analysis study
Authors:
- Donato TorreDTDonato Torre
- Roberto TambiniRTRoberto Tambini
- 2 February 2002
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 3 (1) , 1-8
Abstract
BACKGROUND: HIV-1 resistance tests, both phenotype and genotype, have been entering clinical practice during the last years, but limited prospective studies have been reported in antiretroviral-treated patients with virological failure. PURPOSE: A meta-analysis of randomized controlled trials (RCTs) published or presented at the most important international conferences until February 2001 was performed to estimate the impact of resistance-guided antiretroviral therapy on virological outcome. METHOD: A search for RCTs was performed by using a MEDLINE database, Internet sources, and international conference presentations and was updated September 2001. All RCTs available, including four RCTs on genotype resistance testing, one RCT on phenotype resistance testing, and one RCT on genotypic and phenotypic testing, were analyzed. The rate of patients with undetectable viremia at 3 months was reported in all RCTs and the rate at 6 months was reported in 4 of 6 RCTs. RESULTS: The rate of patients with undetectable viral load after 3 months was 42.6% in patients who were treated based on genotype results and was 33.2% in patients who were treated based on standard of care (SOC; odds ratio [OR] 1.7; 95% CI: 1.3-2.2). At 6 months, undetectable viremia was observed in 38.8% and 28.7% of the patients, respectively (OR: 1.6; 95% CI: 1.2-2.2). In 142 patients, expert advice was provided to optimize clinical use of genotypic data. The higher rate of viral suppression was achieved in this subgroup of patients (50.7% vs. SOC 35.8%; OR 2.4; 95% CI 1.5-3.7). In contrast, undetectable viremia was achieved in 37.5% patients who were treated based on phenotype results versus 33.8% patients who were treated based on SOC (OR 1.1; 95% CI 0.8-1.6). CONCLUSION: These results support the use of a genotypic test in patients experiencing virological failure during antiretroviral treatment. Expert interpretation of the test may increase the probability of virological response. PDF Keywords genotype resistance, HIV-1 therapy, resistance testing Related articles View all related articles var addthis_config = { ui_cobrand: "Taylor & Francis Online", services_compact: "citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more", pubid: "ra-4dff56cd6bb1830b" }; var addthis_config = {"data_track_addressbar":true,"ui_click":true}; Add to shortlist Link Permalink http://dx.doi.org/10.1310/FY66-NVWJ-3332-HW3C Download Citation Recommend to: A friendKeywords
This publication has 18 references indexed in Scilit:
- Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt StudyAIDS, 2000
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000
- Antiretroviral Drug Resistance Testing in Adult HIV-1 InfectionJAMA, 2000
- Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance TherapyJAMA, 2000
- Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 1999
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- HIV-1 Protease Inhibitors Are Substrates for theMDR1 Multidrug TransporterBiochemistry, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985